SRMS Inhibitors
1 drugsAbout SRMS
SRMS is a protein kinase involved in cellular signaling pathways, making it a potential oncology target. Its precise function is still being investigated, but its role suggests therapeutic intervention could be beneficial.
SRMS has potential as a druggable target in oncology, though no genetic evidence currently links it to specific diseases. Further research is needed to understand its contribution to disease progression and identify therapeutic applications.
SRMS is targeted by one FDA-approved drug, ZELBORAF (Roche), a small molecule with two indications in oncology. Roche is the only company with an approved SRMS-targeting drug.
Top SRMS Drugs
Roche is the only company with an approved drug targeting SRMS.
The SRMS market is not competitive, presenting an opportunity for new entrants.
SRMS Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SRMS, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could expand the therapeutic potential of SRMS.
SRMS Clinical Trials 121 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on SRMS. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 46 | 28 | 15 | 2 | 65% |
| Phase 2 | 61 | 25 | 14 | 22 | 64% |
| Phase 3 | 10 | 7 | 1 | 2 | 88% |
| Phase 4 | 4 | 2 | 1 | 1 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved SRMS drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting SRMS. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
SRMS Drug Approval Timeline (2011 - 2011)
The first and most recent drug approval for SRMS was ZELBORAF in 2011.
The SRMS target may be underexplored, suggesting potential for renewed drug development efforts.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 66 (13 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on SRMS. A trial counts if an approved drug acting on SRMS is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.